TABLE 3.
Clinical developments of G12C inhibitor combinations [51].
| G12C inhibitor | Partner | Function | NCT | Clinical phase | Cancer |
|---|---|---|---|---|---|
| sotorasib | AMG404 | PD-1 inhibitor | 03600883 | I/II | NSCLC |
| carboplatin/pemetrexed | chemotherapy | (Japan) | II | NSCLC | |
| palbociclib | CDK4/6 inhibitor | 05178888 | I/Ib | solid tumor | |
| afatinib | EGFR-inhibitor | 04185883 | Ib/II | NSCLC | |
| panitumumab | anti-EGFR | 05198934 | III | CRC | |
| everolimus | mTOR inhibitor | 04185883 | Ib/II | solid tumor | |
| RMC-4630 | SHP2 inhibitor | 04185883 | Ib/II | solid tumor | |
| bevacizumab | anti-VEGF | 05180422 | I/II | NSCLC | |
| adagrasib | pembrolizumab | anti-PD1 | 046113596 | II | NSCLC |
| cetuximab | anti-EGFR | 04793958 | III | CRC | |
| TNO-155 | SHP2 inhibitor | 04330664 | I/II | solid tumor | |
| BI-17011963 | SOS1 inhibitor | 04975256 | I/Ib | solid tumor |
CRC, colorectal cancer; NSCLC, non-small cell lung cancer.